Press releases

Catherine Llorens-Cortes receives the 2014 Galien France pharmaceutical research award for her work on the key role of angiotensin III at brain level in the control of blood pressure

Quantum Genomics receives a 3 M EUR financing

Quantum Genomics announces the appointment of Dr Olivier Madonna as Chief Medical Officer

Quantum Genomics receives all regulatory approvals to start its Phase II clinical trial in hypertension

Publication of an independent equity research by Aurgalys

Quantum Genomics announces the appointment of international experts as members of its Scientific Advisory Board

Quantum Genomics receives financial aid from Bpifrance (France Public Innovation Bank) for its research program evaluating combinations of its new class of molecules with other anti-hypertensive compounds

Professor Pierre Corvol appointed Chairman of the Scientific Advisory Board of Quantum Genomics

Quantum Genomics disclosed the final results of phase I clinical trials for QGC001 during the joint Meeting of the European and International Societies of Hypertension (ESH-ISH) in Athens (Greece)

Quantum Genomics strengthens its management team by appointing Marc Karako, Chief Financial Officer, and Jean-Philippe Milon, Chief Operating Officer

Additional private placement of EUR 240K : total fundraising increased to EUR 3.650 K in 2014

Quantum Genomics transfers its shares to Alternext Paris as of April 10, 2014, following a capital increase of EUR 3.4 million

ANR provides a grant of EUR 1 million for the implementation of a research program with the QGC001